摘要
原发性乳腺淋巴瘤(primary breast lymphoma,PBL)是一种临床上罕见的疾病,占所有乳腺恶性肿瘤的0.5%。其最常见的临床表现是乳房无痛性肿块。因临床表现与影像学表现不典型,确诊依赖于组织病理学与免疫组化。弥漫性大B细胞型淋巴瘤(diffuse large B-cell lymphoma,DLBCL)是最常见的组织学类型。全身化疗联合辅助放疗被认为是标准的治疗方式。手术治疗被认为不能提高患者生存率。利妥昔单抗以及中枢神经系统预防性治疗的作用有待进一步探讨。本文就原发性乳腺淋巴瘤研究新进展进行综述。
Primary breast lymphoma（ PBL） is a rare disease,accounting for about 0. 5% of all breast malignancies.The most typical manifestation is the painless breast lump. Clinical symptoms and radiological performances are nonspecific. Definite diagnosis is mainly relied on pathological biopsy and immunohistochemistry. The most common histopathological category is diffuse large B-cell of the lymphoma（ DLBCL）. Systematic chemotherapy combined with adjuvant radiotherapy are considered to be the standard treatment. Most scholars believe that surgery cannot improve patient survival. The role of rituximab and prophylaxis of the central nervous system in treatment need to be further explored. This review summarizes the most recent advances in primary breast lymphoma research.
出处
《大连医科大学学报》
CAS
2017年第5期499-502,共4页
Journal of Dalian Medical University
关键词
原发性乳腺淋巴瘤
手术
化疗
放疗
预后
primary breast lymphoma
surgery
chemotherapy
radiotherapy
prognosis
